JPWO2023081818A5 - - Google Patents

Info

Publication number
JPWO2023081818A5
JPWO2023081818A5 JP2024526885A JP2024526885A JPWO2023081818A5 JP WO2023081818 A5 JPWO2023081818 A5 JP WO2023081818A5 JP 2024526885 A JP2024526885 A JP 2024526885A JP 2024526885 A JP2024526885 A JP 2024526885A JP WO2023081818 A5 JPWO2023081818 A5 JP WO2023081818A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
cea
fragment
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540374A5 (https=
JP2024540374A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079296 external-priority patent/WO2023081818A1/en
Publication of JP2024540374A publication Critical patent/JP2024540374A/ja
Publication of JP2024540374A5 publication Critical patent/JP2024540374A5/ja
Publication of JPWO2023081818A5 publication Critical patent/JPWO2023081818A5/ja
Pending legal-status Critical Current

Links

JP2024526885A 2021-11-05 2022-11-04 がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用 Pending JP2024540374A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275998P 2021-11-05 2021-11-05
US63/275,998 2021-11-05
US202263336676P 2022-04-29 2022-04-29
US63/336,676 2022-04-29
PCT/US2022/079296 WO2023081818A1 (en) 2021-11-05 2022-11-04 Monoclonal antibodies against carcinoembryonic antigens, and their uses

Publications (3)

Publication Number Publication Date
JP2024540374A JP2024540374A (ja) 2024-10-31
JP2024540374A5 JP2024540374A5 (https=) 2025-11-14
JPWO2023081818A5 true JPWO2023081818A5 (https=) 2025-11-14

Family

ID=86242041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526885A Pending JP2024540374A (ja) 2021-11-05 2022-11-04 がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用

Country Status (7)

Country Link
US (2) US20250251400A1 (https=)
EP (1) EP4426748A4 (https=)
JP (1) JP2024540374A (https=)
KR (1) KR20240099315A (https=)
AU (1) AU2022379952A1 (https=)
CA (1) CA3236417A1 (https=)
WO (1) WO2023081818A1 (https=)

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2217625B1 (en) * 2007-11-08 2021-08-04 Precision Biologics, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
CN105744954B (zh) * 2013-10-18 2021-03-05 豪夫迈·罗氏有限公司 抗rspo2和/或抗rspo3抗体及其用途
WO2020113164A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
CN111004328A (zh) * 2019-12-11 2020-04-14 深圳市国创纳米抗体技术有限公司 一种用于双抗体夹心法检测癌胚抗原的纳米抗体组合

Similar Documents

Publication Publication Date Title
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
EP1455819A1 (en) Individualized anti-cancer antibodies
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
US11009507B2 (en) Methods and diagnostics for cancer detection and treatment monitoring
US20220308059A1 (en) Biomarkers for disease progression in squamous cell carcinoma
JP7086607B2 (ja) Ｉｇｆ－１ｒ抗体および癌の診断のためのその使用
WO2003074568A9 (en) Individualized anti-cancer antibodies
AU2019228339A1 (en) Progastrin as a biomarker for immunotherapy
JPWO2023081818A5 (https=)
WO2020225547A1 (en) Methods of determining the margin of a tumour
BR112017022635B1 (pt) Anticorpo anti-igf-1r, kits, e métodos para a detecção in vitro ou ex vivo da presença e/ou localização de células tumorais expressando igf-1r em um indivíduo, para a detecção in vitro ou ex vivo da percentagem de células tumorais que expressam igf-1r em um indivíduo, para a determinação in vitro ou ex vivo do nível de expressão de igf-1r em células tumorais em um indivíduo, para a determinação in vitro ou ex vivo da pontuação de igf-1r de células tumorais ou de um tumor em um indivíduo, para determinar se um transtorno oncogênico é suscetível ao tratamento com uma droga de anticorpo tendo como alvo a via de igf-1r, para a determinação in vitro ou ex vivo da eficácia de um regime terapêutico conce(...)
JPWO2022076364A5 (https=)